- December 2019
- Pharmaceutical trademarks: the proof of genuine use and proper reason for non-use
- New European Guidance on the qualification and classification of software as medical devices
- Case-law clarifications concerning telemedicine
- The First Italian Case on Electronic Cigarettes’ Advertising
- Under what circumstances may an incumbent associate with a competitor in a public tender? The ICA provides useful guidance in the field of plasma derivatives.
- Medical Devices Regulation: transitional provisions on the validity of certificates issued under the former Directives
- October 2019
- Ban on the marketing of Cannabis sativa L and its derivatives for recreational use: the ruling of the Unified Divisions of the Supreme Court of Cassation
- Artificial Intelligence in healthcare between opportunities and new challenges
- The ranitidine case: a test for the new class action?
- Interruption in the marketing of medicines: AIFA provides clarifications to MAHs on their communication duty
- New criteria for the negotiation of prices for medicines
- Excessive pricing abuses in the pharmaceuticals sector: complying with a cease-and-desist order. The Italian case of Aspen v AGCM
- June 2019
- The EU Court of Justice holds that colluding to disseminate information constitute a restriction of competition “by object” (Roche / Novartis)
- Regulations on the shortage of medicines in the Draft law converting the “Calabria” Law Decree
- Artificial intelligence software: FDA news
- Breaking news on the supplementary protective certificate for medicinal products
- Substitutability of veterinary medicines: this is now also possible through the use of parallel imports
- European Law 2018: amendments to the Drugs Code in regard to the implementation of the GMP
- Selling of medicines through vending machines, clarifications from the Ministry
- Adverse reaction to medicines and pharmaceutical companies’ liability: valuable tips from the Court of Cassation